Apollomics, Inc. (APLM)
NASDAQ: APLM · Real-Time Price · USD
23.57
-0.02 (-0.08%)
Aug 20, 2026, 4:00 PM EDT - Market closed
Apollomics Revenue
In the year 2025, Apollomics had annual revenue of $8.84M with 776.31% growth. Apollomics had revenue of $342.00K in the half year ending December 31, 2025, with 2.70% growth.
Revenue (ttm)
$8.84M
Revenue Growth
+776.31%
P/S Ratio
5.55
Revenue / Employee
$631,571
Employees
14
Market Cap
51.76M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 8.84M | 7.83M | 776.31% |
| Dec 31, 2024 | 1.01M | 545.00K | 117.46% |
| Dec 31, 2023 | 464.00K | -552.00K | -54.33% |
| Dec 31, 2022 | 1.02M | 1.01M | 50,700.00% |
| Dec 31, 2021 | 2.00K | -1.84M | -99.89% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| BioStem Technologies | 34.59M |
| TScan Therapeutics | 7.11M |
| Immutep | 5.28M |
| Alps Group | 3.74M |
| RenovoRx | 1.98M |
| Mereo BioPharma Group | 500.00K |
| aTyr Pharma | 190.00K |
| Impact BioMedical | 35.00K |
APLM News
- 3 days ago - Apollomics announces $10M private placement transaction - TheFly
- 9 days ago - Apollomics Announces $10 Million Private Placement Transaction - GlobeNewsWire
- 4 weeks ago - Apollomics Inc trading resumes - TheFly
- 4 weeks ago - Apollomics Inc trading halted, volatility trading pause - TheFly
- 5 weeks ago - Apollomics regains compliance with Nasdaq listing requirements - TheFly
- 5 weeks ago - Apollomics Regains Full Compliance with Nasdaq Listing Requirements - GlobeNewsWire
- 2 months ago - Apollomics Inc trading resumes - TheFly
- 2 months ago - Apollomics Inc trading halted, volatility trading pause - TheFly